We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+1.86%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$54.7B
AUM Growth
+$1.45B
Cap. Flow
+$1.02B
Cap. Flow %
1.86%
Top 10 Hldgs %
17.33%
Holding
3,009
New
39
Increased
2,170
Reduced
725
Closed
55

Top Buys

Rank Stock Value
1
FIS icon
Fidelity National Information Services
FIS
+$65.3M
2
GPN icon
Global Payments
GPN
+$40.3M
3
MSFT icon
Microsoft
MSFT
+$37.9M
4
LHX icon
L3Harris
LHX
+$32.8M
5
AMZN icon
Amazon
AMZN
+$32.5M

Sector Composition

Rank Sector Weight
1 Technology 18.64%
2 Financials 15.56%
3 Healthcare 12.85%
4 Consumer Discretionary 10.31%
5 Industrials 10.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FTSI
2876
DELISTED
FTS International, Inc. Common Stock
FTSI
$107K ﹤0.01%
2,378
+109
+5% +$7.84K
HNRG icon
2877
Hallador Energy
HNRG
$713M
$106K ﹤0.01%
29,222
+2,646
+10% +$12.5K
DLTH icon
2878
Duluth Holdings
DLTH
$159M
$105K ﹤0.01%
12,390
-100
-0.8% -$1.09K
NMR icon
2879
Nomura Holdings
NMR
$28.5B
$104K ﹤0.01%
24,446
CFMS
2880
DELISTED
Conformis, Inc. Common Stock
CFMS
$104K ﹤0.01%
2,238
-13
-0.6% -$782
BXG
2881
DELISTED
Bluegreen Vacations Corporation Common Stock
BXG
$104K ﹤0.01%
11,164
+947
+9% +$9.61K
KNTK icon
2882
Kinetik
KNTK
$3.58B
$103K ﹤0.01%
3,646
-41
-1% -$1.23K
CELH icon
2883
Celsius Holdings
CELH
$7.55B
$102K ﹤0.01%
87,861
-750
-0.8% -$1.04K
GALT icon
2884
Galectin Therapeutics
GALT
$196M
$100K ﹤0.01%
27,330
+75
+0.3% +$271
AVXL icon
2885
Anavex Life Sciences
AVXL
$292M
$99K ﹤0.01%
31,404
-425
-1% -$1.23K
MRNS
2886
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$99K ﹤0.01%
16,100
-159
-1% -$1.28K
MBII
2887
DELISTED
Marrone Bio Innovations, Inc.
MBII
$99K ﹤0.01%
70,279
+53
+0.1% +$75
AGNT
2888
AGNT Inc
AGNT
$693M
$97K ﹤0.01%
23,232
-350
-1% -$1.66K
ESTE
2889
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
$96K ﹤0.01%
29,542
+2,922
+11% +$12.5K
SND icon
2890
Smart Sand
SND
$193M
$95K ﹤0.01%
33,511
+2,993
+10% +$7.47K
LEAF
2891
DELISTED
Leaf Group Ltd.
LEAF
$95K ﹤0.01%
22,689
+362
+2% +$1.92K
MR
2892
DELISTED
Montage Resources Corporation Common Stock
MR
$95K ﹤0.01%
25,148
+2,789
+12% +$10.7K
STEX
2893
Streamex Corp
STEX
$81.2M
$94K ﹤0.01%
1,143
-15
-1% -$1.16K
PSEC icon
2894
Prospect Capital
PSEC
$1.13B
$94K ﹤0.01%
14,212
+35
+0.2% +$231
MBIO icon
2895
Mustang Bio
MBIO
$4.5M
$93K ﹤0.01%
38
NEXT icon
2896
NextDecade
NEXT
$1.74B
$93K ﹤0.01%
16,105
-100
-0.6% -$537
EYPT icon
2897
EyePoint Inc
EYPT
$978M
$92K ﹤0.01%
5,079
+241
+5% +$3.73K
SBBP
2898
DELISTED
Strongbridge Biopharma plc.
SBBP
$92K ﹤0.01%
38,311
+4,811
+14% +$12.9K
TEF
2899
DELISTED
Telefonica
TEF
$91K ﹤0.01%
+14,742
New +$89.1K
YARW
2900
Yarrow Bioscience, Inc. Common Stock
YARW
$25.3M
$91K ﹤0.01%
6
+1
+20% +$16.1K

Similar funds

RhumbLine Advisers's Q3 2019 Portfolio in Review

As of Q3 2019, RhumbLine Advisers held 3,009 positions worth $54.7B, up 2.7% from $53.3B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Trading was light in Q3 2019: portfolio turnover was 3.1%. RhumbLine Advisers opened 39 new positions and exited 55, leaving the 3,009-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q3 2019 buy was Avantor: 187,780 shares worth $2.76M.
  • RhumbLine Advisers added most to Fidelity National Information Services in Q3 2019, an estimated $65.3M increase.
  • RhumbLine Advisers's biggest Q3 2019 reduction was Leidos, cutting an estimated $15M.
  • RhumbLine Advisers fully exited Anadarko Petroleum in Q3 2019, selling an estimated $64.3M.
  • RhumbLine Advisers's ten largest holdings make up 17% of its $54.7B portfolio in Q3 2019.
  • RhumbLine Advisers opened 39 new positions and closed 55 in Q3 2019.
  • RhumbLine Advisers's portfolio value rose 2.7% quarter-over-quarter to $54.7B.

Based on RhumbLine Advisers's 13F filing for Q3 2019, filed 23 Oct 2019.